The highest rates of HER2 positivity were observed in bladder cancer, uterine serous carcinoma, and esophagogastric junction cancer. New research suggests the incidence of HER2 positivity is low ...
FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...
Human epidermal growth factor receptor 2 (HER2)/neu overexpression, amplification and mutations are associated with an increased metastatic potential in cancer cells and poor prognosis. HER2 signaling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback